CASPAR: A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings

Sponsor

Janssen-Cilag International NV (Industry)

Overall Status

Recruiting

CT.gov ID

NCT04940039

Collaborator

(none)

100

Enrollment

Locations

Arm

33.8

Anticipated Duration (Months)

Patients Per Site

0.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to assess the long-term symptomatic response (Visit 2 [Week 1] to Week 66 [End of Study ]) measured by change in the Clinical Global Impressions -Severity for Schizophrenia (CGI-SS) in participants with schizophrenia who are treated in Rwandan real-world healthcare settings with the antipsychotic regimen that starts with oral anti-psychotic (AP) formulation followed by continued treatment with (paliperidone palmitate 1-month [PP1M] and 3-month [PP3M] formulations).

Condition or Disease	Intervention/Treatment	Phase
Schizophrenia	Drug: Risperidone 3 mg Drug: Paliperidone Palmitate 50 mg eq. Drug: Paliperidone Palmitate 75 mg eq. Drug: Paliperidone Palmitate 100 mg eq. Drug: Paliperidone Palmitate 150 mg eq. Drug: Paliperidone Palmitate 175 mg eq. Drug: Paliperidone Palmitate 263 mg eq. Drug: Paliperidone Palmitate 350 mg eq. Drug: Paliperidone Palmitate 525 mg eq.	Phase 4

Study Design

Study Type:

Interventional

Anticipated Enrollment :

100 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Clinical Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings

Actual Study Start Date :

Jul 22, 2021

Anticipated Primary Completion Date :

May 7, 2024

Anticipated Study Completion Date :

May 15, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Paliperidone Palmitate Participants in Observation Phase will receive their treatment prescribed by treating physicians as part of their usual clinical practice and the standard of care (SoC) treatment for Rwanda mental healthcare settings. Participants who have not received risperidone or paliperidone or paliperidone palmitate earlier in Observation Phase will receive oral risperidone 3 milligram (mg) tablets once daily for 3 days in Run-in Phase to determine tolerability. Participants will receive flexible dose range from 50 to 150 mg equivalent (eq.) long acting formulation of paliperidone palmitate once monthly (PP1M) as an intramuscular (IM) injection in Lead-in Treatment Phase for at least 17 weeks (maximum 25 weeks) and if stable dose is achieved for PP1M, participants will enter Maintenance Treatment Phase and continue to receive flexible dose range from 175 to 525 mg eq. long acting formulation of paliperidone palmitate every 3 months (PP3M) as an IM injection for up to 24 weeks.	Drug: Risperidone 3 mg Participants will receive 3 mg oral risperidone tablet once daily for 3 days. Drug: Paliperidone Palmitate 50 mg eq. Participants will receive 50 mg eq. PP1M IM injection for at least 17 weeks (maximum 25 weeks). Other Names: R092670 Drug: Paliperidone Palmitate 75 mg eq. Participants will receive 75 mg eq. PP1M IM injection for at least 17 weeks. Other Names: R092670 Drug: Paliperidone Palmitate 100 mg eq. Participants will receive 100 mg eq. PP1M IM injection for at least 17 weeks. Other Names: R092670 Drug: Paliperidone Palmitate 150 mg eq. Participants will receive 150 mg eq. PP1M IM injection for at least 17 weeks. Other Names: R092670 Drug: Paliperidone Palmitate 175 mg eq. Participants will receive 175 mg eq. PP3M IM injection up to 24 weeks. Other Names: R092670 Drug: Paliperidone Palmitate 263 mg eq. Participants will receive 263 mg eq. PP3M IM injection up to 24 weeks. Other Names: R092670 Drug: Paliperidone Palmitate 350 mg eq. Participants will receive 350 mg eq. PP3M IM injection up to 24 weeks. Other Names: R092670 Drug: Paliperidone Palmitate 525 mg eq. Participants will receive 525 mg eq. PP3M IM injection up to 24 weeks. Other Names: R092670

Arm

Intervention/Treatment

Experimental: Paliperidone Palmitate

Participants in Observation Phase will receive their treatment prescribed by treating physicians as part of their usual clinical practice and the standard of care (SoC) treatment for Rwanda mental healthcare settings. Participants who have not received risperidone or paliperidone or paliperidone palmitate earlier in Observation Phase will receive oral risperidone 3 milligram (mg) tablets once daily for 3 days in Run-in Phase to determine tolerability. Participants will receive flexible dose range from 50 to 150 mg equivalent (eq.) long acting formulation of paliperidone palmitate once monthly (PP1M) as an intramuscular (IM) injection in Lead-in Treatment Phase for at least 17 weeks (maximum 25 weeks) and if stable dose is achieved for PP1M, participants will enter Maintenance Treatment Phase and continue to receive flexible dose range from 175 to 525 mg eq. long acting formulation of paliperidone palmitate every 3 months (PP3M) as an IM injection for up to 24 weeks.

Drug: Risperidone 3 mg

Participants will receive 3 mg oral risperidone tablet once daily for 3 days.

Drug: Paliperidone Palmitate 50 mg eq.

Participants will receive 50 mg eq. PP1M IM injection for at least 17 weeks (maximum 25 weeks).

Other Names:

R092670

Drug: Paliperidone Palmitate 75 mg eq.

Participants will receive 75 mg eq. PP1M IM injection for at least 17 weeks.

Other Names:

R092670

Drug: Paliperidone Palmitate 100 mg eq.

Participants will receive 100 mg eq. PP1M IM injection for at least 17 weeks.

Other Names:

R092670

Drug: Paliperidone Palmitate 150 mg eq.

Participants will receive 150 mg eq. PP1M IM injection for at least 17 weeks.

Other Names:

R092670

Drug: Paliperidone Palmitate 175 mg eq.

Participants will receive 175 mg eq. PP3M IM injection up to 24 weeks.

Other Names:

R092670

Drug: Paliperidone Palmitate 263 mg eq.

Participants will receive 263 mg eq. PP3M IM injection up to 24 weeks.

Other Names:

R092670

Drug: Paliperidone Palmitate 350 mg eq.

Participants will receive 350 mg eq. PP3M IM injection up to 24 weeks.

Other Names:

R092670

Drug: Paliperidone Palmitate 525 mg eq.

Participants will receive 525 mg eq. PP3M IM injection up to 24 weeks.

Other Names:

R092670

Outcome Measures

Primary Outcome Measures

Mean Change in Clinical Global Impression Severity of Schizophrenia (CGI-SS) Score from Visit 2 (Week 1) to Visit 14 (Week 66 [End of Study {EOS}]) [Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])]
The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (1 indicates none to 7 indicates extreme symptoms).

Secondary Outcome Measures

Mean Change in CGI-SS Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS]) [Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])]
The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (1 indicates none to 7 indicates extreme symptoms).
Change in CGI-SS Score from Visit 2 (Week 1) to Visit 6 (Week 25) [Visit 2 (Week 1) to Visit 6 (Week 25)]
The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (1 indicates none to 7 indicates extreme symptoms).
Change in Personal and Social Performance (PSP) Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS]) [Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])]
The PSP scale assesses the degree of difficulty a participant exhibits over a 7-day period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The impairment of each domain is rated on a 6-point basis, including absent (0), mild (1), moderate (2), marked (3), severe (4), and very severe (5). The higher domain score, therefore, indicates, worse functioning in that area.
Maintenance of Treatment Effect as Assessed by PSP Scale Scores from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS]) [Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])]
The PSP scale assesses the degree of difficulty a participant exhibits over a 7-day period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The impairment of each domain is rated on a 6-point basis, including absent (0), mild (1), moderate (2), marked (3), severe (4), and very severe (5). The higher domain score, therefore, indicates, worse functioning in that area.
Change in PSP Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25) [Visit 2 (Week 1) to Visit 6 (Week 25)]
The PSP scale assesses the degree of difficulty a participant exhibits over a 7-day period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The impairment of each domain is rated on a 6-point basis, including absent (0), mild (1), moderate (2), marked (3), severe (4), and very severe (5). The higher domain score, therefore, indicates, worse functioning in that area.
Change in Patient Satisfaction Rating Scale Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS]) [Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])]
The patient satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 [very dissatisfied] to 5 [very satisfied]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Maintenance of Treatment Effect as Assessed by Patient Satisfaction Rating Scale Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS]) [Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])]
The patient satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 [very dissatisfied] to 5 [very satisfied]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Change in Patient Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25) [Visit 2 (Week 1) to Visit 6 (Week 25)]
The patient satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 [very dissatisfied] to 5 [very satisfied]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Change in Clinician Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS]) [Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])]
The clinician satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 [very dissatisfied] to 5 [very satisfied]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Maintenance of Treatment Effect as Assessed by Clinician Satisfaction Rating Scale Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS]) [Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])]
The clinician satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 [very dissatisfied] to 5 [very satisfied]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Change in Clinician Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25) [Visit 2 (Week 1) to Visit 6 (Week 25)]
The clinician satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 [very dissatisfied] to 5 [very satisfied]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Change in Schizophrenia Quality of Life Scale (SQLS) Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS]) [Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])]
The SQLS has 33 items covering topics such as psychosocial feelings and vitality. Response options are never, rarely, sometimes, often, or always. Scoring algorithms yield a 0 to 100 scale, with higher scores indicating lower quality of life.
Maintenance of Treatment Effect as Assessed by SQLS Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS]) [Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])]
The SQLS has 33 items covering topics such as psychosocial feelings and vitality. Response options are never, rarely, sometimes, often, or always. Scoring algorithms yield a 0 to 100 scale, with higher scores indicating lower quality of life.
Change in SQLS Score from Visit 2 (Week 1) to Visit 6 (Week 25) [Visit 2 (Week 1) to Visit 6 (Week 25)]
The SQLS has 33 items covering topics such as psychosocial feelings and vitality. Response options are never, rarely, sometimes, often, or always. Scoring algorithms yield a 0 to 100 scale, with higher scores indicating lower quality of life.

Eligibility Criteria

Criteria

Ages Eligible for Study:

19 Years to 34 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Diagnosis of schizophrenia by Mini International Neuropsychiatric Interview (MINI)-Screen / MINI (Module K) that requires treatment initiation or a change in treatment to better address safety, efficacy, or adherence limitations of current treatment
Eligible for treatment in the Rwandan mental healthcare system
At least moderately ill as measured by the Clinical Global Impression - Severity of Schizophrenia (CGI-SS) scale for schizophrenia (rating of greater than or equal to [>=] 4). This criterion needs to be re-confirmed at Visit 2
Has a primary caregiver who is willing to participate in this study (caregiver should be knowledgeable about the participant's condition, provide economic/cost of care information, and is expected to be with the participant for greater than [>] 24 hours each week for the duration of the study)
A woman of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) during screening
Able to give consent to participate in a clinical study that includes treatment with risperidone and long-acting injectable (LAI) formulations of paliperidone palmitate. Participants must be willing to receive injections. The participant and the caregiver must sign their own informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study

Exclusion Criteria:

Has a physical, mental, or legal incapacity that prevents a valid consent or capacity to complete about 12 months of treatment with antipsychotic medication and compliance with this study protocol
History of organic brain syndromes, comorbid psychiatric and/or physical illnesses, or significant comorbid substance abuse that is likely to interfere with understanding of or compliance with study requirements
Known allergies, hypersensitivity, or intolerance to risperidone or Paliperidone palmitate or its excipients
Received an investigational intervention including investigational vaccines or used an invasive investigational medical device within 30 days before the planned first dose of study intervention, or is currently enrolled in an investigational study
Pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study intervention
Poor prior response to risperidone or paliperidone

Contacts and Locations

Locations

	Site	City	Country	Postal Code
1	University Teaching Hospital of Butare(CHUB)	Butare	Rwanda	NAP
2	Kibuye Referral Hospital	Kibuye	Rwanda	POBOX44
3	CARAES Ndera Neuro-Psychiatric Hospital	Kigali	Rwanda	423
4	University Teaching Hospital of Kigali	Kigali	Rwanda	KN4
5	Rwamagana Provincial Hospital	Rwamagana	Rwanda